Quoin Pharma Q1 net loss $2.6M; cash $17M; first patient dosed in Netherton trial

Quoin Pharmaceuticals, Ltd.

Net loss $2.6M for Q1 2023 vs $1.7M in Q1 2022; cash & equivalents $17.0M as of March 31, 2023.
First patient dosed in open-label trial of QRX003 for Netherton Syndrome patients on off-label systemic therapy.
Recruiting and dosing continue in double-blinded, placebo-controlled study of QRX003 for Netherton Syndrome.
Completed public offering in Feb 2023 with net proceeds ~$5.8M, extending cash runway into 2H 2024.
Two rare disease programs with Queensland University of Technology; expect clinical testing in Australia in 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quoin Pharmaceuticals, Ltd. reported the first quarter of 2023 results: net income approximately $2.6 million.

Period: the first quarter of 2023
Net income: approximately $2.6 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023 was approximately $2.6 million compared to approximately $1.7 million for the quarter ended March 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-23-057256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.